Metropolis Healthcare (NSE:METROPOLIS) EBIT: ₹2,837 Mil (TTM As of Mar. 2026)


NSE:METROPOLIS Metropolis Healthcare Ltd NSE:METROPOLIS
95 GF Score
Price ₹567.95
GF Value ₹588.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Metropolis Healthcare EBIT?

Metropolis Healthcare NSE:METROPOLIS +1.41% 95 EBIT is ₹2,837 Mil as of Mar. 2026. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review.

Metropolis Healthcare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹777 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,837 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Metropolis Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 was 11.10%. Metropolis Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 73.54%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Metropolis Healthcare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.41%.


Metropolis Healthcare  (NSE:METROPOLIS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Metropolis Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2777.084 * ( 1 - 26.95% )/( (0 + 18277.238)/ 1 )
=2028.659862/18277.238
=11.10 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21380.546 - 1757.408 - ( 2156.452 - max(0, 3340.221 - 4686.121+2156.452))
=18277.238

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Metropolis Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3107.82/( ( (0 + max(0, 0)) + (4100.14 + max(125.904, 0)) )/ 1 )
=3107.82/( ( 0 + 4226.044 )/ 1 )
=3107.82/4226.044
=73.54 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1702.853 + 454.937 + 371.879) - (1757.408 + 0 + 646.357)
=125.904

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Metropolis Healthcare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2837.194/117813.273
=2.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Metropolis Healthcare EBIT Related Terms


Metropolis Healthcare EBIT Historical Data

* Premium members only.

The historical data trend for Metropolis Healthcare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metropolis Healthcare EBIT Chart

Metropolis Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,130.93 2,143.05 1,972.25 2,094.28 2,837.19

Metropolis Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 406.43 664.29 767.08 628.87 776.96

NSE:METROPOLIS vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Metropolis Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metropolis Healthcare EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Metropolis Healthcare's EV-to-EBIT falls into.


NSE:METROPOLIS
95GF Score
Metropolis Healthcare Ltd NSE:METROPOLIS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metropolis Healthcare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,837 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹2,837 Mil mean?
Metropolis Healthcare (NSE:METROPOLIS) has a EBIT of ₹2,837 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Metropolis Healthcare.
Is Metropolis Healthcare's EBIT too high?
Metropolis Healthcare's current EBIT is ₹2,837 Mil. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's EBIT compare to TMO and DHR?
Metropolis Healthcare's EBIT of ₹2,837 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Metropolis Healthcare. Metropolis Healthcare's current EBIT is ₹2,837 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current EBIT is ₹2,837 Mil. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current EBIT is ₹2,837 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued. The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25. GuruFocus considers Metropolis Healthcare to be Fairly Valued.

Key valuation signals for NSE:METROPOLIS:

  • EBIT: ₹2,837 Mil
  • GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Metropolis Healthcare Business Description

Other Exchanges 542650:India
Address Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score

Get the complete analysis for NSE:METROPOLIS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹567.95
Price
₹588.25
GF Value